Filing Details

Accession Number:
0000919574-23-003449
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-23 17:46:54
Reporting Period:
2023-05-19
Accepted Time:
2023-05-23 17:46:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
834365 Biolife Solutions Inc BLFS Electromedical & Electrotherapeutic Apparatus (3845) 943076866
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534260 Casdin Partners Gp, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534261 Casdin Capital, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534264 Eli Casdin 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
1534265 Casdin Partners Master Fund, L.p. 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $.001 Per Share Acquisiton 2023-05-19 50,000 $22.55 125,027 No 4 P Indirect See footnote
Common Stock, Par Value $.001 Per Share Acquisiton 2023-05-22 24,973 $21.86 150,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $.001 Per Share 7,571,535 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $22.07753 to $23.0197. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.
  3. The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.